Advanced Non-Small-Cell Lung Cancer
9
1
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
AK112 in Advanced Non-Small Cell Lung Cancer
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer
Tislelizumab as Cross-line Treatment for Advanced NSCLC
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
Multimodality Treatment Including Curative Resection of Advanced NSCLC